Almost half of pharmaceutical industry profits continue to come from biopharmaceuticals.
David Lin
Advertisement
David Lin, dlin@bioplanassociates.com, is the senior director, Technical Research, BioPlan Associates. With a Master’s in Molecular Biology, he has many years experience with biopharmaceutical and pharmaceutical life science research, including a diverse science and marketing background. Specializing in content creation and market research, www.bioplanassociates.com.
Articles by David Lin
Advertisement
Latest Updated Articles
Trends Affecting Biopharmaceutical ManufacturingSeptember 1st 2021
Advertisement
Advertisement
Trending on BioPharm International
1
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
2
FDA Reportedly Pauses National Priority Voucher Pilot and Pauses CRL Publication
3
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
4
FDA Clears IND for Biolojic’s BD200, the First AI-Designed Multibody ADC to Enter Clinical Trials
5